WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205781
Description: Triphendiol, also known as NV-196, is a synthetic isoflavene . Triphendiol (NV-196) is another investigational drug in the Marshall Edwards, Inc., oncology drug pipeline. Triphendiol is broadly cytostatic and cytotoxic against most forms of human cancer cells in vitro, and has been shown to cause cell cycle arrest (or stop cells increasing in number) and to induce apoptosis (or initiate programmed cell death) in various cancer cell lines.
MedKoo Cat#: 205781
Chemical Formula: C22H20O4
Exact Mass: 348.13616
Molecular Weight: 348.3918
Elemental Analysis: C, 75.84; H, 5.79; O, 18.37
Synonym: Triphendiol; NV196; NV-196; NV 196.
IUPAC/Chemical Name: (3S,4R)-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)chroman-7-ol
InChi Key: KQCJZAUNKSGEFM-IFMALSPDSA-N
InChi Code: InChI=1S/C22H20O4/c1-25-18-9-4-15(5-10-18)22-19-11-8-17(24)12-21(19)26-13-20(22)14-2-6-16(23)7-3-14/h2-12,20,22-24H,13H2,1H3/t20-,22-/m1/s1
SMILES Code: OC1=CC2=C(C=C1)[C@@H](C3=CC=C(OC)C=C3)[C@@H](C4=CC=C(O)C=C4)CO2
Triphendiol is a derivative of phenoxodiol and was selected for further development based on superior anti-cancer activity against a range of cancers, especially pancreas and bile duct cancers and melanoma. In non-clinical studies, triphendiol invoked cell cycle arrest leading to programmed cell death in cell lines representative of late stage pancreatic, and bile duct carcinoma. Apoptosis induction was independent of p53 status and proceeded via the mitochondrial cell death pathway. We have also demonstrated that triphendiol is able to sensitize cell lines representative of both pancreatic cancer and cholangiocarcinoma (bile duct cancer) to the standard of care drug, gemcitabine. Proof of concept studies in animal models of pancreatic cancer and cholangiocarcinoma, demonstrated that orally delivered triphendiol is effective at inhibiting tumour proliferation and limiting terminal tumour burden. In further GLP compliant toxicology studies, triphendiol was shown to be non-clastogenic and non-mutagenic, and is well tolerated in rodent and non-rodent chronic repeat dose studies when delivered orally. These data have indicated that clinical development of triphendiol as a biliary cancer therapeutic is warranted. Two Phase Ia clinical studies have been completed investigating triphendiol pharmacokinetics and safety when delivered either orally or as an intravenous infusion. No medication related adverse events were reported. (source: http://www.novogen.com).
1: Wang X, McKernan R, Kim KH, Alvero AB, Whiting A, Thompson JA, Mor G, Saif MW, Husband AJ, Brown DM, Tytler EM. Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs. 2011 Sep;22(8):719-31. PubMed PMID: 21666438.